Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
40.17
+0.54 (1.36%)
At close: May 19, 2026, 4:00 PM EDT
39.00
-1.17 (-2.91%)
After-hours: May 19, 2026, 7:06 PM EDT

Enliven Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
34.1467.647.5518.967.7713
Research & Development
81.65171.71161.5664.5731.0238.44
Total Operating Expenses
115.79239.32209.1183.5338.7951.44
Operating Income
-115.79-119.66-104.55-83.53-38.79-51.44
Interest Income
17.0116.0114.8911.971.130.23
Other Non-Operating Income (Expense)
-0.05-0.050.87-0.02--0.18
Total Non-Operating Income (Expense)
17.0115.9615.5311.951.130.06
Pretax Income
-98.78-103.69-89.02-71.58-37.66-51.38
Provision for Income Taxes
-0.05-0.23---
Net Income
-98.78-103.69-89.02-71.58-37.66-51.38
Net Income to Common
-98.78-103.69-89.02-71.58-37.66-51.38
Shares Outstanding (Basic)
6057473633
Shares Outstanding (Diluted)
6057473633
Shares Change (YoY)
21.89%20.38%32.43%1037.74%-10.25%-
EPS (Basic)
-1.67-1.83-1.89-2.01-12.05-9.48
EPS (Diluted)
-1.67-1.83-1.89-2.01-12.05-9.48
Shares Outstanding
60.8959.4448.9441.2926.2926.29
Free Cash Flow
-65.6-70.46-73.24-61.42-32.69-46.78
Free Cash Flow Per Share
-1.10-1.24-1.56-1.73-10.46-13.44
EBITDA
-115.5-119.62-103.81-87.84-38.58-51.19
EBIT
-115.79-119.66-104.55-83.53-38.79-51.44
Effective Tax Rate
0.05%0.00%-0.26%0.00%0.00%0.00%
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q